Intralabyrinthine Vestibular Schwannoma Responsive to Intratympanic Gentamicin Treatment.

Related Articles

Intralabyrinthine Vestibular Schwannoma Responsive to Intratympanic Gentamicin Treatment.

J Int Adv Otol. 2017 Aug;13(2):285-288

Authors: Covelli E, Volpini L, Filippi C, Tarantini S, Marrone V, Monini S, Barbara M

Abstract
Intralabyrinthine schwannoma (ILS) is a rare benign tumor that affects the ends of cochlear and vestibular nerves. In a majority of the cases, it occurs with unilateral progressive sensorineural hearing loss. Less frequent symptoms include tinnitus, imbalance, vertigo, or fullness. The advent of magnetic resonance imaging allows early diagnosis and enables an appropriate therapeutic protocol. This report describes a case of intravestibular schwannoma, with fluctuating hearing loss and intractable vertigo, treated with intratympanic gentamicin. The patient was a 28-year-old woman with intractable vertigo and fluctuating left-side hearing loss caused by left intravestibular schwannoma. Because surgery was temporarily rejected by the patient, a single dose of intratympanic gentamicin was administered. Following this, the patient showed a significant improvement in the symptoms. However, moderate to flat sensorineural hearing loss was also observed. Intratympanic gentamicin infiltration is a valid therapeutic option for patients with ILS, affected by intractable vertigo, when the patient refuses surgery.

PMID: 28816698 [PubMed - indexed for MEDLINE]

http://ift.tt/2wmSqYd